Abstract
Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors [Corrigendum] Wu H, Infante JR, Keedy VL, et al. On page 1208, Disclosure section, “The authors report no conflicts of interest in the work” has been updated since publication. Read the original article
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
